Vanda Pharmaceuticals Inc. (VNDA) stock
VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3059% below fair value
$3.44−0.23 (-6.13%)
Close on Nov 20, 2026Market cap $208.32MP/E –Yield –
Vanda Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Vanda Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $229.28M, up 8.1% year over year. For fiscal 2025 it was $216.11M, up 8.7% from the year before. Over ten years it grew 7.0% a year on average. The highest annual figure on record is $268.68M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $216.11M | +8.7% |
| FY2024 | Dec 31, 2024 | $198.77M | +3.2% |
| FY2023 | Dec 31, 2023 | $192.64M | -24.3% |
| FY2022 | Dec 31, 2022 | $254.38M | -5.3% |
| FY2021 | Dec 31, 2021 | $268.68M | +8.3% |
| FY2020 | Dec 31, 2020 | $248.17M | +9.2% |
| FY2019 | Dec 31, 2019 | $227.19M | +17.6% |
| FY2018 | Dec 31, 2018 | $193.12M | +17.0% |
| FY2017 | Dec 31, 2017 | $165.08M | +13.1% |
| FY2016 | Dec 31, 2016 | $146.02M | +32.8% |
| FY2015 | Dec 31, 2015 | $109.93M | +119.2% |
| FY2014 | Dec 31, 2014 | $50.16M | +48.0% |
| FY2013 | Dec 31, 2013 | $33.88M | +3.5% |
| FY2012 | Dec 31, 2012 | $32.73M | +4.7% |
| FY2011 | Dec 31, 2011 | $31.27M | -12.4% |
| FY2010 | Dec 31, 2010 | $35.71M | +685.2% |
| FY2009 | Dec 31, 2009 | $4.55M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $69.82M | +24.1% |
| Q2 FY2026 | Jun 30, 2026 | $50.53M | -3.9% |
| Q1 FY2026 | Mar 31, 2026 | $51.72M | +3.4% |
| Q4 FY2025 | Dec 31, 2025 | $57.22M | +7.6% |
| Q3 FY2025 | Sep 30, 2025 | $56.26M | +18.1% |
| Q2 FY2025 | Jun 30, 2025 | $52.59M | +4.2% |
| Q1 FY2025 | Mar 31, 2025 | $50.04M | +5.4% |
| Q4 FY2024 | Dec 31, 2024 | $53.19M | +17.5% |
| Q3 FY2024 | Sep 30, 2024 | $47.65M | +22.8% |
| Q2 FY2024 | Jun 30, 2024 | $50.47M | +9.6% |
| Q1 FY2024 | Mar 31, 2024 | $47.46M | -24.1% |
| Q4 FY2023 | Dec 31, 2023 | $45.27M | -29.8% |
| Q3 FY2023 | Sep 30, 2023 | $38.82M | -40.6% |
| Q2 FY2023 | Jun 30, 2023 | $46.06M | -28.5% |
| Q1 FY2023 | Mar 31, 2023 | $62.50M | +3.8% |
| Q4 FY2022 | Dec 31, 2022 | $64.48M | -5.2% |
| Q3 FY2022 | Sep 30, 2022 | $65.32M | -6.8% |
| Q2 FY2022 | Jun 30, 2022 | $64.39M | -5.2% |
| Q1 FY2022 | Mar 31, 2022 | $60.19M | -4.0% |
| Q4 FY2021 | Dec 31, 2021 | $68.02M | +0.5% |
| Q3 FY2021 | Sep 30, 2021 | $70.10M | +16.2% |
| Q2 FY2021 | Jun 30, 2021 | $67.90M | +9.2% |
| Q1 FY2021 | Mar 31, 2021 | $62.67M | +8.1% |
| Q4 FY2020 | Dec 31, 2020 | $67.65M | +11.0% |
| Q3 FY2020 | Sep 30, 2020 | $60.31M | +1.4% |
| Q2 FY2020 | Jun 30, 2020 | $62.21M | +5.3% |
| Q1 FY2020 | Mar 31, 2020 | $58.00M | +21.6% |
| Q4 FY2019 | Dec 31, 2019 | $60.93M | +14.9% |
| Q3 FY2019 | Sep 30, 2019 | $59.49M | +21.1% |
| Q2 FY2019 | Jun 30, 2019 | $59.06M | +24.7% |
| Q1 FY2019 | Mar 31, 2019 | $47.71M | +9.5% |
| Q4 FY2018 | Dec 31, 2018 | $53.04M | +19.8% |
| Q3 FY2018 | Sep 30, 2018 | $49.14M | +18.9% |
| Q2 FY2018 | Jun 30, 2018 | $47.35M | +12.6% |
| Q1 FY2018 | Mar 31, 2018 | $43.59M | +16.5% |
| Q4 FY2017 | Dec 31, 2017 | $44.28M | +15.8% |
| Q3 FY2017 | Sep 30, 2017 | $41.34M | – |
| Q2 FY2017 | Jun 30, 2017 | $42.06M | – |
| Q1 FY2017 | Mar 31, 2017 | $37.42M | – |
| Q4 FY2016 | Dec 31, 2016 | $38.24M | – |
See a number that looks wrong?